A Phase II Study of Ipilimumab and Nivolumab Immunotherapy plus Cabozantinib to Treat Rare Advanced Genitourinary Cancers

Full Title

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) (A031702) (CIRB)

Purpose

The purpose of this study is to assess the safety and effectiveness of treating rare advanced genitourinary cancers with the immunotherapies nivolumab and ipilimumab plus the drug cabozantinib.

Nivolumab and ipilimumab take the brakes off the immune response, enabling immune cells to find and destroy cancer cells. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The use of these drugs in combination in this study is considered investigational. Nivolumab and ipilimumab are given intravenously (by vein) and cabozantinib is taken orally (by mouth).